Geodesic
Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement
Y. Kogan1 ; B. Ribba1 ; K. Marron1 ; N. Dahan2 ; V. Vainstein1 ; Z. Agur1, 2
1 Institute for Medical Biomathematics (IMBM), POB 282 Hate'ena 10, Bene Ataroth, 60991 Israel
2 Optimata Ltd, 7 Abba Hillel Silver St., Ramat-Gan, 52522 Israel
Mathematical modelling of natural phenomena, Tome 2 (2007) no. 3, pp. 47-68.

Voir la notice de l'article provenant de la source EDP Sciences

Despite recent advances, treatment of patients with aggressive Non-Hodgkin's lymphoma (NHL2) has yet to be optimally designed. Notwithstanding the contribution of molecular treatments, intensification of chemotherapeutic regimens may still be beneficial. Hoping to aid in the design of intensified chemotherapy, we put forward a mathematical and computational model that analyses the effect of Doxorubicin on NHL over a wide range of patho-physiological conditions. The model represents tumour growth both in diffusion-limited settings, that is, in small avascular tumours and tumour cords, and in perfusion-limited settings, e.g. in well-vascularized tumours. Model simulations indicated the presence of a critical regimen intensity below which treatment will fall short of tumour elimination. Taking this critical intensity into account, we compared two regimen intensification strategies: Dose escalation and regimen densification, i.e. reducing the inter-dosing interval. In the diffusion-limited setting, dose escalation was somewhat more efficient than regimen densification. In the perfusion-limited setting, both intensification strategies yielded similar results. The present study coupled with a realistic myelotoxicity model may add insight on the optimisation of NHL intensified chemotherapy design.
DOI : 10.1051/mmnp:2007003

Y. Kogan 1 ; B. Ribba 1 ; K. Marron 1 ; N. Dahan 2 ; V. Vainstein 1 ; Z. Agur 1, 2

1 Institute for Medical Biomathematics (IMBM), POB 282 Hate'ena 10, Bene Ataroth, 60991 Israel
2 Optimata Ltd, 7 Abba Hillel Silver St., Ramat-Gan, 52522 Israel 
@article{MMNP_2007_2_3_a2,
     author = {Y. Kogan and B. Ribba and K. Marron and N. Dahan and V. Vainstein and Z. Agur},
     title = {Intensified {Doxorubicin-Based} {Regimen} {Efficacy} in {Residual} {Non-Hodgkin's} {Lymphoma} {Disease:} {Towards} a {Computationally} {Supported} {Treatment} {Improvement}},
     journal = {Mathematical modelling of natural phenomena},
     pages = {47--68},
     publisher = {mathdoc},
     volume = {2},
     number = {3},
     year = {2007},
     doi = {10.1051/mmnp:2007003},
     language = {en},
     url = {http://geodesic.mathdoc.fr/articles/10.1051/mmnp:2007003/}
}
TY  - JOUR
AU  - Y. Kogan
AU  - B. Ribba
AU  - K. Marron
AU  - N. Dahan
AU  - V. Vainstein
AU  - Z. Agur
TI  - Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement
JO  - Mathematical modelling of natural phenomena
PY  - 2007
SP  - 47
EP  - 68
VL  - 2
IS  - 3
PB  - mathdoc
UR  - http://geodesic.mathdoc.fr/articles/10.1051/mmnp:2007003/
DO  - 10.1051/mmnp:2007003
LA  - en
ID  - MMNP_2007_2_3_a2
ER  - 
%0 Journal Article
%A Y. Kogan
%A B. Ribba
%A K. Marron
%A N. Dahan
%A V. Vainstein
%A Z. Agur
%T Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement
%J Mathematical modelling of natural phenomena
%D 2007
%P 47-68
%V 2
%N 3
%I mathdoc
%U http://geodesic.mathdoc.fr/articles/10.1051/mmnp:2007003/
%R 10.1051/mmnp:2007003
%G en
%F MMNP_2007_2_3_a2
Y. Kogan; B. Ribba; K. Marron; N. Dahan; V. Vainstein; Z. Agur. Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement. Mathematical modelling of natural phenomena, Tome 2 (2007) no. 3, pp. 47-68. doi : 10.1051/mmnp:2007003. http://geodesic.mathdoc.fr/articles/10.1051/mmnp:2007003/

Cité par Sources :